45th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130295073 | Use of pegylated recombinant human arginase for treatment of leukemia - The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia. | 2013-11-07 |
20130295074 | Pyridoxamine for the Treatment of Diabetic Kidney Disease - The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient. | 2013-11-07 |
20130295075 | COMPOSITIONS AND METHODS OF TREATING GLAUCOMA - Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided. | 2013-11-07 |
20130295076 | MCPIP AS WOUND THERAPY - Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 2013-11-07 |
20130295077 | TREATMENT OF SANFILIPPO SYNDROME TYPE B - Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety. | 2013-11-07 |
20130295078 | METHOD OF IMPROVING ABSORPTION OF VITAMIN E BY A PET ANIMAL - A method of providing a pet with a benefit relating to effective assimilation of a lipid is described wherein the pet is administered, as a part of, or in addition to its regular diet, an edible composition that contains an ingredient that maintains, promotes or enhances the capacity of the pet to digest lipid efficiently. The invention extends to compositions for use in promoting lipid assimilation in pets, particularly senior or elderly pets. The compositions include pancreatic, liver and intestinal mucosa function-promoters. In embodiments, the liver function-promoter may be selected from taurine, emulsifiers, vitamins, minerals, glutathione and glutathione promoters. | 2013-11-07 |
20130295079 | Pharmaceutical composition for strengthening spleen and stomach and preparation method therefor - A pharmaceutical composition for strengthening spleen and stomach and a preparation method therefor. The method includes the step of mixing four substances listed below to obtain a mixture, wherein the mixture is the pharmaceutical composition for strengthening spleen and stomach, and the four substances are (A) ginseng ethanol extract, (B) volatile oil of largehead atractylodes rhizome and tangerine peels, (C) aqueous extract of Indian bread, yamaimo, lotus seeds, tangerine peels, liquorice root, hawthorn fruit, germinated barley, largehead atractylodes rhizome and rhizoma alismatis; (D) fermentation broth of fruits and vegetables. | 2013-11-07 |
20130295080 | Pharmaceutical composition for treating melasma and preparation method thereof - A pharmaceutical composition for treating melasma is provided. The pharmaceutical composition is prepared from ginseng, salvia, mint, orange peel, peony, poria, licorice, peach seed, yam, | 2013-11-07 |
20130295081 | Polyurethane Composite for Wound Healing and Methods Thereof - The presently-disclosed subject matter includes polyurethane composites that include tissue component(s), as well as methods of making such composites and uses thereof. The polyurethane component can comprise a polyisocyanate prepolymer and a polyol. The tissue component can be a polysaccharide. Exemplary composites can be moldable and/or injectable, and can cure into a porous composite that provides mechanical strength and/or supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shaped areas, voids, or the like. Exemplary composites can be used for treating wounds. | 2013-11-07 |
20130295082 | ANTIBODY FORMULATIONS AND METHODS - Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis. | 2013-11-07 |
20130295083 | 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes - A method of treating islet cell transplant patients is described herein. The method comprises the steps of a) identifying an islet cell transplant patient, b) treating the patient with 2AMD or 2AMD analog and c) observing a prolonged period of normal glycemia is disclosed. A composition for treatment of islet cell transplant patient is disclosed as well, wherein the composition comprises 50-400 ng/day of 2AMD or 2AMD analog. | 2013-11-07 |
20130295084 | BINDING PROTEINS HAVING TETHERED LIGHT CHAINS - The present invention relates to binding proteins having tethered light chains and methods of making and using them. | 2013-11-07 |
20130295085 | ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY - Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein. | 2013-11-07 |
20130295086 | ANTIBODIES SELECTIVE FOR CELLS PRESENTING EGFR AT HIGH DENSITY - Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells. | 2013-11-07 |
20130295087 | METHODS OF TREATING CHRONIC PAIN - The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody. | 2013-11-07 |
20130295088 | METHODS OF TREATING INFLAMMATORY PAIN - The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody. | 2013-11-07 |
20130295089 | METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTRIIA ANTIBODY - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2013-11-07 |
20130295090 | HUMANIZED MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND AND/OR NEUTRALIZE JAPANESE ENCEPHALITIS VIRUS (JEV) AND THEIR USE - Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies. | 2013-11-07 |
20130295091 | COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTIGEN BINDING ANTIBODIES - The present invention relates to a combination therapy including tumor associated antigen binding antibodies. | 2013-11-07 |
20130295092 | Method for the Treatment of Neurodegenerative Diseases - Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia. | 2013-11-07 |
20130295093 | FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker. | 2013-11-07 |
20130295094 | USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS - The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization. | 2013-11-07 |
20130295095 | MONOCLONAL ANTIBODIES TARGETING AMYLOID BETA OLIGOMERS - The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated Aβ starting with pyroglutamate (AβρE), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing Aβ oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said AβρE oligomers, and a method for identifying agents useful in the treatment and/or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and/or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation characterized by the presence of Aβ oligomers in a subject. | 2013-11-07 |
20130295096 | DEGRADED AGONIST ANTIBODY - The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. | 2013-11-07 |
20130295097 | Human Antibodies to Fel d1 and Methods of Use Thereof - The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen. | 2013-11-07 |
20130295098 | MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF - The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. | 2013-11-07 |
20130295099 | N-LINKEDGLYCAN COMPOUNDS - An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a | 2013-11-07 |
20130295100 | MARKERS FOR ACUTE KIDNEY INJURY AND USES THEREOF - The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury. | 2013-11-07 |
20130295101 | Ricin Vaccine and Methods of Making Thereof - Disclosed herein ricin toxin A chain polypeptides having an engineered disulfide bond ((SS)RTA) and compositions thereof. The disclosed (SS)RTA polypeptides retain the immunological epitope of wild type RTA, lack detectable N-glycosidase activity or exhibit reduced N-glycosidase activity as compared to controls, and exhibit increased solubility, thermal stability and a lower tendency to self-aggregate as compared to RTA 198 and/or RTA 1-33/44-198. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, inhibiting, reducing and/and preventing ricin intoxication are disclosed. | 2013-11-07 |
20130295102 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P - The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5). | 2013-11-07 |
20130295103 | ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL) - The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer. | 2013-11-07 |
20130295104 | CD37-Binding Molecules and Immunoconjugates Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 2013-11-07 |
20130295105 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 2013-11-07 |
20130295106 | Frizzled-Binding Agents And Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided. | 2013-11-07 |
20130295107 | ANTIBODY TO HUMAN IL-3 RECEPTOR ALPHA CHAIN - The present invention provides an antibody to human IL-3Rα chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3Rα chain but does not bind to C domain of the human IL-3Rα chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3Rα as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3Rα antibody as an active ingredient. | 2013-11-07 |
20130295108 | METHOD FOR TREATING SYNOVIAL SARCOMA - Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided. | 2013-11-07 |
20130295109 | USES OF ANTIBODIES - The present invention provides a method of preparing an antibody containing milk or egg product for use in preventing and/or treating of a non infectious medical condition. The invention also provides non-systemic modes of administering pharmaceutical compositions including the antibody containing milk or egg products, including to the GI tract. | 2013-11-07 |
20130295110 | PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS - The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer. | 2013-11-07 |
20130295111 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERACTIVE IMMUNE SYSTEM - The present invention provides methods and compositions for treating disorders associated with hyperactive immune responses. The invention also provides methods for lithibiting activation of CD4 | 2013-11-07 |
20130295112 | Antibodies Against Nerve Growth Factor (NGF) With Enhanced In Vivo Stability - The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided. | 2013-11-07 |
20130295113 | ANTI-ERYTHROPOIETIN ANTIBODIES - The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies. | 2013-11-07 |
20130295114 | PVRL4 (Nectin4) is a Receptor for Measles Virus - PVRL4 is a tumor marker that is highly expressed on the surfaces of many carcinomas. Disclosed herein are compositions and methods that provide impetus for using measles virus as an oncolytic agent against PVRL4+ carcinomas and use of PVRL4-binding agents to interfere with viral infection. | 2013-11-07 |
20130295115 | COMPOSITIONS AND METHODS FOR TREATING ALPHAVIRUS INFECTION - Provided herein are compositions and methods for treating a disease or disorder associated with an alphavirus infection. Specifically, the invention relates to administering a Natural Resistance-Associated Macrophage Protein (NRAMP) antagonist to prevent binding or infection of an alphavirus to its host. | 2013-11-07 |
20130295116 | THERAPEUTIC ANTIBODIES - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 2013-11-07 |
20130295117 | ALDOSTERONE INDUCED ELASTIN PRODUCTION - Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein. | 2013-11-07 |
20130295118 | ANTIBODIES SPECIFIC FOR CLL-1 - Provided herein are antibodies specific for CLL-1. | 2013-11-07 |
20130295119 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 2013-11-07 |
20130295120 | VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON ANTIGEN-PRESENTING CELLS - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 2013-11-07 |
20130295121 | Covalent Diabodies and Uses Thereof - Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule. | 2013-11-07 |
20130295122 | ELASTIN DIGEST COMPOSITIONS AND METHODS UTILIZING SAME - The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides. Methods of using these elastin digest comprising compositions for treating tissues in need of increased elasticity and or Elastin are described. | 2013-11-07 |
20130295123 | VACCINE COMPRISING AMB A 1 PEPTIDES FOR USE IN THE TREATMENT OF RAGWEED ALLERGY - The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen. | 2013-11-07 |
20130295124 | ORF7 DEFICIENT VARICELLA VIRUS, VACCINE COMPRISING THE VIRUS AND USE THEREOF - Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus. | 2013-11-07 |
20130295125 | COMPOSITIONS AND METHODS RELATING TO MOUSE PAPILLOMA VIRUS - Methods and compositions for detecting MusPV, also known as MmuPv1, infection of a rodent subject are described according to aspects of the present invention. In specific aspects, the present invention relates to assays for detecting MusPV infection of a rodent subject; vaccine compositions for inducing an immunological response against MusPV in a rodent subject; methods of inducing an immunological response to MusPV in a rodent subject; isolated MusPV protein; isolated antibodies which specifically binds to an MusPV protein, a fragment or variant thereof; isolated recombinantly expressed MusPV proteins; expression constructs comprising a nucleic acid encoding an MusPV protein; host cells comprising the expression construct; and hybridoma cell lines expressing an anti-MusPV monoclonal antibody specific for MusPV. | 2013-11-07 |
20130295126 | VACCINES FOR INCLUSION BODY HEPATITIS - A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny. | 2013-11-07 |
20130295127 | VACCINE AGAINST CLOSTRIDIUM PERFRINGENS - There is provided a vaccine for controlling | 2013-11-07 |
20130295128 | CHIMERIC VACCINES - The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient. | 2013-11-07 |
20130295129 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF - Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject. | 2013-11-07 |
20130295130 | COMPOSITION FOR PROMOTING LIPOLYSIS - It is an object of the present invention to provide a composition containing lactoferrin and another component and having a prominent effect of promoting visceral lipolysis. That is, the present invention is a composition for promoting the lipolysis; a food product, a feedstuff or a pharmaceutical product including (A) lactoferrin and (B) one or more ingredients selected from the group consisting of a | 2013-11-07 |
20130295131 | GENERATION OF ANTIGENIC VIRUS-LIKE PARTICLES THROUGH PROTEIN-PROTEIN LINKAGES - We have generated virus-like particles (VLPs) that can display other proteins through covalent protein-protein linkages mediated by the ‘Dock and Lock’ interaction between the | 2013-11-07 |
20130295132 | Conjugation of Streptococcal Capsular Saccharides - Three conjugation methods for use with the capsular saccharide of | 2013-11-07 |
20130295133 | RECOMBINANT VIRUS EXPRESSING FOREIGN DNA ENCODING FELINE CD80, FELINE CD86, FELINE CD28, OR FELINE CTLA-4 AND USES THEREOF - The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropriate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline. The present invention also comprises recombinant viruses which are capable of suppressing an immune response in a feline. | 2013-11-07 |
20130295134 | RECOMBINANT BICISTRONIC FLAVIVIRUS VECTORS - This invention relates to bicistronic | 2013-11-07 |
20130295135 | FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 2013-11-07 |
20130295136 | LIVE ATTENUATED CATFISH VACCINE AND METHOD OF MAKING - A high throughput bioluminescence mutant screening procedure is disclosed. This procedure utilizes robotics, and bacterial luciferase to allow real-time monitoring of mutant viability. The procedure was used to decelop a live attenuated vaccine for a catfish against | 2013-11-07 |
20130295137 | Compositions And Methods For Treatment Of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2013-11-07 |
20130295138 | ROADMAP FOR CONTROLLING MALARIA - Embodiments of the present invention concern methods of preventing malaria in a target population of humans comprising: uniformly administering a therapeutically effective amount of a live low dose malaria vaccine to each individual within the target population on each of two or three consecutive days. The methods include using | 2013-11-07 |
20130295139 | ADJUVANT COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO POLYNUCLEOTIDE-BASED VACCINES - The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE. | 2013-11-07 |
20130295140 | TESTOSTERONE OLFACTION - A composition of an olfactory stimulus mechanism for stimulating the production of testosterone. A method of increasing the level of testosterone in an individual by smelling the truffle extract, causing androgens in the truffle extract to attach to the olfactory bulb in the individual, and inducing testosterone production. A method of preventing the onset of Alzheimer's disease in an individual by the individual smelling the truffle extract, and inducing testosterone production in the individual. A method of treating symptoms of menopause in a woman by the woman smelling the truffle extract, and inducing testosterone production in the woman. A method of treating andropause in a man by a man smelling the truffle extract, and inducing testosterone production in the man. | 2013-11-07 |
20130295141 | MATRIX METALLOPROTEINASE INHIBITORS - The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase. | 2013-11-07 |
20130295142 | IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH ALPHA CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V-ALPHA-J-ALPHA, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS - The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease. | 2013-11-07 |
20130295143 | ELECTROPROCESSING OF ACTIVE PHARMACEUTICAL INGREDIENTS - Electrospinning of crystalline particles comprising active pharmaceutical ingredients (API) from suspensions yields fibrous compositions comprising the API. The morphology and size of the crystalline particles may be preserved. The particles may be predominantly retained by fibers and distributed throughout the fibrous mesh. Tablet forms of the APIs prepared from the fibrous compositions demonstrate higher dissolution rates than tablets prepared from compacted powders of the APIs. | 2013-11-07 |
20130295144 | MIXING DEVICE - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids. The electrokinetically-altered fluid compositions and methods of producing the fluid include electrokinetically-altered ionic aqueous fluids optionally in the form of solvated electrons stabilized with molecular oxygen. | 2013-11-07 |
20130295145 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING ETODOLAC - The present invention relates to stable pharmaceutical compositions comprising nano size droplets of etodolac or salts thereof along with other pharmaceutically acceptable excipients. These compositions exhibit greater permeability, and improved bioavailability leading to enhanced therapeutic activity. The invention also relates to processes for the preparation of such compositions. | 2013-11-07 |
20130295146 | Composition for Improving Membrane Composition and Functioning of Cells - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises:
| 2013-11-07 |
20130295147 | GAS-FILLED MICROVESICLES FOR USE AS VACCINE - Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells. | 2013-11-07 |
20130295148 | SOLID COSMETIC MAKEUP AND/OR CARE COMPOSITION - The present invention relates to a solid cosmetic makeup and/or care composition comprising: —at least 30% by weight of a pulverulent phase relative to its total weight, and—at least 15% by weight of non-volatile oil(s) relative to its total weight, said composition being in the form of a powder. It also targets a corresponding makeup and/or care method. | 2013-11-07 |
20130295149 | POLYUREA MICROCAPSULES - The present invention relates to polyurea core-shell microcapsules having a polyurea shell comprising the reaction product of a polyisocyanate with guanazole and an amino acid. The invention concerns the capsules themselves as well as perfuming compositions and perfumed articles containing them and a process for producing them. | 2013-11-07 |
20130295150 | ELECTRICITY-GENERATING PARTICULATES AND THE USE THEREOF - The invention features a galvanic particulate including a first conductive material and a second conductive material, wherein both the first conductive material and the second conductive material are exposed on the surface of the particulate, wherein the particle size of the particulate is from about 10 nanometers to about 100 micrometers, wherein the second conductive material comprises from about 0.01 percent to about 10 percent, by weight, of the total weight of the particulate, and wherein the difference of the standard potentials of the first conductive material and the second conductive material is at least about 0.2 V. | 2013-11-07 |
20130295151 | PROCESS FOR THE TREATMENT OF CELLULOSIC MOLDED BODIES - The present invention relates to a process for the treatment of a cellulosic molded body, wherein the molded body is contacted with an acid solution of a chitosan. The process according to the invention is characterized in that the chitosan has a deacetylation degree of at least 80%, a nitrogen content of at least 7 w %, preferably at least 7.5 w %, a weight average molecular weight M | 2013-11-07 |
20130295152 | Agrochemical Formulation Comprising Encapsulated Pesticide - The present invention relates to a aqueous composition containing a suspended pesticide A, and microcapsules comprising a shell and a core, wherein the core contains a pesticide B and an aprotic, polar solvent B, and the shell contains poly(meth)acrylate, which comprises C | 2013-11-07 |
20130295153 | Apparatus and Method for Controlled Release of Botanical Fumigant Pesticides - A fumigant pesticide composition made up of a base formula and enhancement formula, which include botanical essential oil-based active ingredients and inert materials identified under the United States Environmental Protection Agency's approved list of minimum risk pesticides. The enhancement formula is effective to inhibit or enhance the release of the secondary metabolites of the essential oil-based active ingredients. An apparatus and method for the controlled release of the fumigant pesticide composition is also disclosed. | 2013-11-07 |
20130295154 | POLY(METH)ACRYLATE BASED MICROCAPSULES COMPRISING PHEROMONE - The present invention relates to a microcapsule comprising a capsule core, which contains a pheromone, and a capsule wall, which contains in polymerized form 30 to 90% by weight of one or more C | 2013-11-07 |
20130295155 | CONTROLLED TIME-RELEASE ALGAE RESISTANT ROOFING SYSTEM - Time-release algae-resistant roofing granules have a base particle including an algaecide and an outer coating layer including another algaecide. The at least two algaecides are released over different predetermined periods. The outer layer protects the base particle from exposure to the environment for a predetermined period, then fails catastrophically so that the interior algaecide can be released. | 2013-11-07 |
20130295156 | PROGENITOR ENDOTHELIAL CELL CAPTURING WITH A DRUG ELUTING IMPLANTABLE MEDICAL DEVICE - A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis. | 2013-11-07 |
20130295157 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES - The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release. | 2013-11-07 |
20130295158 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 2013-11-07 |
20130295159 | METHOD AND SYSTEM FOR SYSTEMIC DELIVERY OF GROWTH ARRESTING, LIPID-DERIVED BIOACTIVE COMPOUNDS - A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting. | 2013-11-07 |
20130295160 | ANTAGONISTS OF MIR-196A - A miR-196a antagonist capable of inhibiting a miR-196a activity, the miR-196a antagonist comprising one or more target sites for miR-196a. Included is also an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more miR-196a antagonists capable of inhibiting a miR-196a activity. In one example, the one or more miR-196a antagonists comprise at least one stem-loop structure comprising a guide strand that comprises a sequence that is complementary to miR-196a, the stem-loop structure further comprising a passenger strand that comprises a mismatch. | 2013-11-07 |
20130295161 | Compositions and Methods for Wound Healing - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osteoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. | 2013-11-07 |
20130295162 | FLAVIVIRUS DOMAIN III VACCINE - The disclosure provides a tetravalent Dengue virus vaccine, and methods of inducing a immune response against a Flavivirus such as Dengue virus 1-4 using the vaccine. The disclosure also provides methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dill polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses. | 2013-11-07 |
20130295163 | NON-REDUCING END MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF - An object of the present invention is to provide a glucan containing at least one residue selected from an N-acetylglucosamine residue and a galactose residue, and a modified product. The branched glucan of the present invention is a branched glucan wherein the branched glucan has a plurality of non-reducing ends and at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an α-1,4-bond to each of two or more non-reducing ends of the branched α-1,4-glucan, but neither an N-acetylglucosamine residue nor a galactose residue is present at the position other than the non-reducing ends of the branched α-1,4-glucan. | 2013-11-07 |
20130295164 | Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria - The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of | 2013-11-07 |
20130295165 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an attenuated or inactivated virus in combination with a non-ionic surfactant vesicle (NISV). | 2013-11-07 |
20130295166 | TESTOSTERONE FORMULATIONS - The subject invention provides improved testosterone gel formulations. | 2013-11-07 |
20130295167 | ENHANCED IMMUNE RESPONSE IN BOVINE SPECIES - The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease. | 2013-11-07 |
20130295168 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2013-11-07 |
20130295169 | Pharmaceutical Compositions Containing Dimethyl Fumarate - Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w. | 2013-11-07 |
20130295171 | KRILL OIL AND REACTED ASTAXANTHIN COMPOSITION AND ASSOCIATED METHOD - A method of enhancing cardiovascular health includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S′-astaxanthin derived from | 2013-11-07 |
20130295172 | Medical compositions, methods of making and using those compositions, and kits including those compositions - Disclosed here are compositions comprising powdered hemp seed, an emulsifier/dispersant such as lecithin (particularly soya lecithin), cannabis, and optionally other additives and excipients. Also described are methods of making the compositions. The compositions may be used, for instance, in the treatment of pain and for their anti-emetic (anti-nausea and anti-vomiting) properties, as well as for the treatment of anorexia and appetite enhancement. Kits containing the compositions, arranged for proper sequential dosing, and optionally including instructions for use are also disclosed. | 2013-11-07 |
20130295173 | COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS - The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms. | 2013-11-07 |